KRAS G12C抑制剂临床获得性耐药:新型开关II口袋突变与多克隆RAS-MAPK再激活
本文报道一例KRAS G12C非小细胞肺癌患者在接受MRTX849(adagrasib)治疗中出现多克隆获得性耐药,系列cfDNA检出跨KRAS、NRAS、BRAF、MAP2K1四基因的10种异质性耐药改变,均汇聚于RAS-MAPK信号再激活。新发现的KRAS Y96D突变影响开关II口袋,干扰药物结合并导致对失活态抑制剂耐药,而活性态抑制剂RM-018可保留结合并抑制KRAS G12C/Y96D、克服耐药。
要点
- KRAS G12C抑制剂获得性耐药可表现为多克隆RAS-MAPK再激活。
- 新型KRAS Y96D开关II口袋突变可致失活态抑制剂结合受损而耐药。
- 活性态抑制剂RM-018可抑制KRAS G12C/Y96D并克服该耐药。
核心结论
- KRAS G12C抑制剂临床获得性耐药的核心机制之一是多克隆RAS-MAPK信号再激活。
- 新型KRAS Y96D开关II口袋突变通过损害药物结合导致对失活态KRAS G12C抑制剂耐药,但可被功能不同的KRAS G12C活性态抑制剂RM-018克服。
研究设计与样本
- 本文为病例报告类研究,描述一例KRAS G12C非小细胞肺癌患者接受MRTX849治疗后出现获得性耐药的机制分析。
- 研究采用系列游离DNA(cfDNA)检测耐药改变,并在工程化及患者来源的KRAS G12C肿瘤模型中验证突变功能。
主要发现
- 该患者在MRTX849治疗中出现多克隆获得性耐药,系列cfDNA检出跨KRAS、NRAS、BRAF、MAP2K1四基因的10种异质性耐药改变。
- 上述10种耐药改变均汇聚于RAS-MAPK信号再激活。
- 新发现的KRAS Y96D突变影响开关II口袋(MRTX849及其他失活态抑制剂结合位点),干扰关键蛋白-药物相互作用。
- 在工程化和患者来源的KRAS G12C肿瘤模型中,KRAS Y96D突变 confer 对失活态抑制剂的耐药。
- 新型三复合物KRAS G12C活性态抑制剂RM-018保留结合并抑制KRAS G12C/Y96D的能力,可克服该耐药。
临床怎么用
- 对KRAS G12C抑制剂治疗后进展的患者,可通过系列cfDNA监测多克隆RAS-MAPK再激活相关耐药改变。
- 检出KRAS Y96D等开关II口袋突变时,提示对失活态KRAS G12C抑制剂耐药,可考虑功能不同的活性态KRAS G12C抑制剂策略。
局限性
- 本文基于单例患者,耐药机制的普遍性需更大样本验证。
- RM-018克服KRAS Y96D耐药的结果主要来自工程化及患者来源模型,尚缺乏临床数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mutant-selective KRASG12C inhibitors, such as MRTX849 (adagrasib) and AMG 510 (sotorasib), have demonstrated efficacy in KRAS G12C-mutant cancers, including non-small cell lung cancer (NSCLC). However, mechanisms underlying clinical acquired resistance to KRASG12C inhibitors remain undetermined. To begin to define the mechanistic spectrum of acquired resistance, we describe a patient with KRAS G12C NSCLC who developed polyclonal acquired resistance to MRTX849 with the emergence of 10 heterogeneous resistance alterations in serial cell-free DNA spanning four genes (KRAS, NRAS, BRAF, MAP2K1), all of which converge to reactivate RAS-MAPK signaling. Notably, a novel KRAS Y96D mutation affecting the switch-II pocket, to which MRTX849 and other inactive-state inhibitors bind, was identified that interferes with key protein-drug interactions and confers resistance to these inhibitors in engineered and patient-derived KRAS G12C cancer models. Interestingly, a novel, functionally distinct tricomplex KRASG12C active-state inhibitor RM-018 retained the ability to bind and inhibit KRASG12C/Y96D and could overcome resistance. SIGNIFICANCE: In one of the first reports of clinical acquired resistance to KRASG12C inhibitors, our data suggest polyclonal RAS-MAPK reactivation as a central resistance mechanism. We also identify a novel KRAS switch-II pocket mutation that impairs binding and drives resistance to inactive-state inhibitors but is surmountable by a functionally distinct KRASG12C inhibitor.See related commentary by Pinnelli and Trusolino, p. 1874.This article is highlighted in the In This Issue feature, p. 1861.
引用
- Tanaka N, Lin JJ, Li C, et al. Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation. Cancer Discov. 2021. PMID: 33824136. doi:10.1158/2159-8290.CD-21-0365
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。